An inhibitor of HDAC1-3 and KDM1A; reduces cell viability in a panel of CRC cell lines at 1-10 μM and in patient-derived CRC cell lines at 5 μM; induces cell cycle arrest at the G2/M phase in HT-29 cells and primary human CRC cells at 5 μM; increases apoptosis in HT-29 cells in a concentration-dependent manner, an effect that is enhanced by the Akt inhibitors perifosine and MK-2206; reduces tumor growth in an HT-29 mouse xenograft model at 100 mg/kg, p.o., every other day when administered alone and to an enhanced degree when co-administered with oxaliplatin